Sarepta Exercises its Exclusive Option to Acquire Myngonexus Therapeutics for $165M
Shots:
- Sarepta exercises its option to acquire Myonexus Therapeutics- in all stock transaction for $165M with its five Limb-girdle muscular dystrophy (LGMDs) gene therapies programs i.e LGMD2E- LGMD2D- LGMD2B- LGMD2L & LGMD2C
- In May-2018 Sarepta and Myonexus collaborated to develop and advance multiple gene therapy programs for LGMD- paying $60M upfront & milestones- gaining excsluive option to acquire Myngonexus
- LGMD2E- LGMD2D- LGMD2B- LGMD2L & LGMD2C are gene therapy programs targeted for MYO-101 (P-I/II)- MYO-102 (P-I/II)- MYO-201 (P-I)- MYO-301 & MYO-103 respectively
Ref: Sarepta Therapeutics | Image: Twitter
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com